Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / VACC - Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20 2023 | Benzinga


VACC - Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20 2023 | Benzinga

  • OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced it will host a Key Opinion Leader (KOL) Webinar to discuss the current treatment landscape for people living with chronic Hepatitis B Virus (HBV) infection and potential paths to a functional cure. Details are as follows:

    KOL Webinar: Seeking a Functional Cure for Chronic Hepatis B
    Wednesday, September 20, 2023 between 14:00-15:00 ET.
    To register for the event, click here.

    The event will feature the following renowned thought leaders who will discuss the current treatment landscape for patients with HBV, combination approaches to enhancing rates of functional cure and the potential of antigen-specific immunotherapeutic approaches:

    • Eleanor Barnes, MBBS, PhD, FRCP, FMedSci, Professor of Hepatology and Experimental Medicine and a Ludwig Adjunct Scholar; University of Oxford, Nuffield Department of Medicine, and co-inventor of VTP-300.
    • Ed Gane, MBChB, MD, FRACP, MNZM, Professor of Medicine, University of Auckland, New Zealand; Chief Hepatologist, Transplant Physician and Deputy Director of the New Zealand Liver Transplant Unit at Auckland City Hospital.

    The Vaccitech management team will provide a clinical overview of VTP-300, the first antigen-specific immunotherapy that has been shown to induce sustained reductions in Hepatitis B surface antigen, a marker of the disease. Vaccitech is studying VTP-300, including in combination with siRNA and low-dose anti-PD-1 antibodies, as part of the search for a regimen that could lead to a potential functional cure for HBV.

    Vaccitech currently has two ongoing trials in HBV. A Phase 2b clinical trial (HBV003; NCT05343481) to evaluate timing of ...

    Full story available on Benzinga.com

  • Stock Information

    Company Name: Vaccitech plc
    Stock Symbol: VACC
    Market: NASDAQ

    Menu

    VACC VACC Quote VACC Short VACC News VACC Articles VACC Message Board
    Get VACC Alerts

    News, Short Squeeze, Breakout and More Instantly...